Creo Medical Group PLC (CREO) - Total Liabilities
Based on the latest financial reports, Creo Medical Group PLC (CREO) has total liabilities worth GBX9.10 Million GBX (≈ $1.11K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Creo Medical Group PLC (CREO) equity growth momentum to track the company's year-over-year net asset growth rate.
Creo Medical Group PLC - Total Liabilities Trend (2005–2025)
This chart illustrates how Creo Medical Group PLC's total liabilities have evolved over time, based on quarterly financial data. See CREO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Creo Medical Group PLC Competitors by Total Liabilities
The table below lists competitors of Creo Medical Group PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AI Era Corp.
NASDAQ:ABQQD
|
USA | $2.73 Million |
|
Sentoria Group Bhd
KLSE:5213
|
Malaysia | RM446.97 Million |
|
B Yair Building Corporation 1988 Ltd
TA:BYAR
|
Israel | ILA10.75 Million |
|
Geiger Counter Limited
LSE:GCL
|
UK | GBX11.26 Million |
|
Xplore Resources Corp
V:XPLR
|
Canada | CA$637.17K |
|
Arkle Resources PLC
STU:48O
|
Germany | €615.00K |
|
Troubadour Resources Inc
V:TR
|
Canada | CA$444.50K |
Liability Composition Analysis (2005–2025)
This chart breaks down Creo Medical Group PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CREO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Creo Medical Group PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Creo Medical Group PLC (2005–2025)
The table below shows the annual total liabilities of Creo Medical Group PLC from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX9.10 Million ≈ $1.11K |
-59.73% |
| 2024-12-31 | GBX22.60 Million ≈ $2.75K |
+34.52% |
| 2023-12-31 | GBX16.80 Million ≈ $2.04K |
-35.22% |
| 2022-12-31 | GBX25.93 Million ≈ $3.16K |
-4.97% |
| 2021-12-31 | GBX27.29 Million ≈ $3.32K |
-7.98% |
| 2020-12-31 | GBX29.66 Million ≈ $3.61K |
+429.58% |
| 2019-12-31 | GBX5.60 Million ≈ $681.39 |
+175.45% |
| 2018-12-31 | GBX2.03 Million ≈ $247.37 |
-11.22% |
| 2018-06-30 | GBX2.29 Million ≈ $278.63 |
+55.67% |
| 2017-06-30 | GBX1.47 Million ≈ $178.99 |
+86.50% |
| 2016-06-30 | GBX788.81K ≈ $95.98 |
+48.05% |
| 2016-02-29 | GBX532.79K ≈ $64.83 |
+80.01% |
| 2015-02-28 | GBX295.98K ≈ $36.01 |
+18.30% |
| 2014-02-28 | GBX250.20K ≈ $30.44 |
+331.38% |
| 2008-02-29 | GBX58.00K ≈ $7.06 |
-76.33% |
| 2007-02-28 | GBX245.00K ≈ $29.81 |
+49.39% |
| 2006-02-28 | GBX164.00K ≈ $19.95 |
+864.71% |
| 2005-02-28 | GBX17.00K ≈ $2.07 |
-- |
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices del… Read more